LivaNova (NASDAQ:LIVN) Shares Cross Below 50-Day Moving Average – Time to Sell?

Shares of LivaNova PLC (NASDAQ:LIVN) passed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $79.65 and traded as low as $74.11. LivaNova shares last traded at $75.44, with a volume of 1,056,361 shares.

Analysts Set New Price Targets

A number of research firms have commented on LIVN. Stifel Nicolaus set a $85.00 target price on LivaNova in a report on Wednesday, August 5th. Needham & Company LLC upped their price target on shares of LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Piper Sandler reiterated an “overweight” rating and issued a $90.00 price target (up from $87.00) on shares of LivaNova in a report on Wednesday, September 2nd. KeyCorp raised their price objective on shares of LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, June 22nd. Finally, Weiss Ratings raised shares of LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, August 18th. Six equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $84.12.

LivaNova Stock Performance

The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. The company has a market capitalization of $4.22 billion, a PE ratio of 22.67 and a beta of 0.87. The stock has a 50-day simple moving average of $79.57 and a 200 day simple moving average of $74.01.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The business had revenue of $390.59 million during the quarter, compared to analysts’ expectations of $380.50 million. During the same quarter last year, the business posted $1.05 earnings per share. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. Equities analysts anticipate that LivaNova PLC will post 3.78 EPS for the current fiscal year.

Insider Transactions at LivaNova

In other news, Director Francesco Bianchi sold 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $78.01, for a total transaction of $273,035.00. Following the completion of the transaction, the director directly owned 4,434 shares of the company’s stock, valued at $345,896.34. This trade represents a 44.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Brooke Story sold 2,300 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $81.42, for a total transaction of $187,266.00. Following the transaction, the director directly owned 7,488 shares of the company’s stock, valued at approximately $609,672.96. This trade represents a 23.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 7,450 shares of company stock valued at $591,839. 0.35% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Tidal Investments LLC acquired a new position in shares of LivaNova in the second quarter valued at approximately $204,000. WINTON GROUP Ltd acquired a new position in LivaNova in the 2nd quarter valued at $4,824,000. Integrated Wealth Concepts LLC purchased a new position in shares of LivaNova during the 2nd quarter worth $119,000. Squarepoint Ops LLC purchased a new position in shares of LivaNova during the 2nd quarter worth $1,418,000. Finally, Allworth Financial LP boosted its holdings in shares of LivaNova by 93.5% during the second quarter. Allworth Financial LP now owns 298 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and manufactures technologies for the treatment of neurological and cardiovascular conditions. The company serves hospitals, physicians and patients in markets around the world, with operations and commercial activities spanning North America, Europe and other international markets.

LivaNova’s Neuromodulation business produces vagus nerve stimulation (VNS) systems marketed under the VNS Therapy brand. These implantable devices are used as an adjunctive treatment for drug-resistant epilepsy and are designed to deliver programmed electrical stimulation to the vagus nerve.